We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu
Trial record 1 of 10 for:    "Mucopolysaccharidosis type VII"
Previous Study | Return to List | Next Study

An Open-Label Phase 1/2 Study to Assess the Safety, Efficacy and Dose of Study Drug UX003 Recombinant Human Beta-glucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With MPS 7

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: May 17, 2013
Last Update Posted: December 6, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Ultragenyx Pharmaceutical Inc

UX003-CL201 is an open-label Phase 1/2 study to assess the safety, efficacy, and dose of UX003 in MPS 7 subjects via IV administration every other week (QOW) for 36 weeks with up to an additional 36 weeks from the optional continuation period. Up to 5 subjects, who are between 5 and 30 years of age inclusive, will be enrolled and treated with UX003.

The initial 12-week treatment period will be followed by a 24-week forced dose titration period to assess the optimal dose. Subjects who complete both the initial treatment and forced dose titration periods will continue treatment in a 36 week continuation period

Condition Intervention Phase
Mucopolysaccharidosis Type 7 Drug: UX003 Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Phase 1/2 Study to Assess the Safety, Efficacy and Dose of UX003 rhGUS Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7)

Resource links provided by NLM:

Further study details as provided by Ultragenyx Pharmaceutical Inc:

Primary Outcome Measures:
  • Safety and tolerability of UX003 as measured by severity and number of Adverse Events (AEs) [ Time Frame: 36 weeks ]
  • Efficacy as determined by reduction of total urinary glycosaminoglycan (uGAG) excretion [ Time Frame: 36 weeks ]

Secondary Outcome Measures:
  • Walking capacity as measured by the 6 Minute Walk Test (6MWT). [ Time Frame: 36 weeks ]
  • Stair climbing capacity as measured by the 3 Minute Stair Climb Test [ Time Frame: 36 weeks ]
  • Pulmonary function as measured by Forced Vital Capacity(FVC), Forced Expiratory Volume (FEV1) and Maximal Voluntary Ventilation (MVV1) [ Time Frame: 36 weeks ]
  • Height and weight growth velocity compared to estimated pretreatment growth rate velocity from medical records (prepubertal pediatric patients only). [ Time Frame: 36 weeks ]
  • Shoulder range of motion as measured by goniometry. [ Time Frame: 36 wks ]
  • Acceptable dose as determined by total uGAG excretion using a forced dose titration regimen [ Time Frame: 36 weeks ]

Enrollment: 3
Study Start Date: October 2013
Study Completion Date: July 2016
Primary Completion Date: July 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: UX003 Drug: UX003


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   5 Years to 30 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Confirmed diagnosis of MPS 7 based on leukocyte or fibroblast glucuronidase enzyme assay or genetic testing confirming diagnosis.
  • Elevated uGAG excretion at a minimum of 2-fold over normal.
  • Between 5 and 30 years of age, inclusive (approximately two subjects between the ages of 20-30 years).
  • Willing and able to provide written, signed informed consent, or in the case of subjects under the age of 18 (or 16 years, depending on the region), provide written assent (if required) and written informed consent by a legally authorized representative after the nature of the study has been explained, and prior to any research-related procedures.
  • Sexually active subjects must be willing to use an acceptable method of contraception while participating in the study.
  • Females of childbearing potential must have a negative pregnancy test at Screening and be willing to have additional pregnancy tests during the study. Females considered not of childbearing potential include those who have had tubal ligation at least one year prior to Screening, or who have had total hysterectomy.

Exclusion Criteria:

  • Has undergone a successful bone marrow or stem cell transplant or has any degree of detectable chimaerism with donor cells.
  • Any known hypersensitivity to rhGUS or its excipients that, in the judgment of the Investigator, places the subject at increased risk for adverse effects.
  • Pregnant or breastfeeding at Screening or planning to become pregnant (self or partner) at any time during the study.
  • Use of any investigational product (drug or device or combination) within 30 days prior to Screening, or requirement for any investigational agent prior to completion of all scheduled study assessments at any time during the study.
  • Has a condition of such severity and acuity, in the opinion of the Investigator, that it warrants immediate surgical intervention or other treatment or may not allow safe study participation.
  • Has a concurrent disease or condition that, in the view of the Investigator, places the subject at high risk of poor treatment compliance or of not completing the study, or would interfere with study participation or affect safety.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01856218

United Kingdom
Manchester Academic Health Science Centre
Manchester, United Kingdom
Sponsors and Collaborators
Ultragenyx Pharmaceutical Inc
Principal Investigator: Simon Jones, MD Univeristy of Manchester
  More Information

Responsible Party: Ultragenyx Pharmaceutical Inc
ClinicalTrials.gov Identifier: NCT01856218     History of Changes
Other Study ID Numbers: UX003-CL201
First Submitted: May 8, 2013
First Posted: May 17, 2013
Last Update Posted: December 6, 2017
Last Verified: May 2017

Keywords provided by Ultragenyx Pharmaceutical Inc:
Mucopolysaccharidosis type 7, MPS 7, Sly syndrome, enzyme replacement therapy, rare disease, lysosomal storage disease, metabolic disorder

Additional relevant MeSH terms:
Carbohydrate Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Lysosomal Storage Diseases
Connective Tissue Diseases
Metabolic Diseases